Weiss Ratings Reaffirms "Sell (D)" Rating for Oramed Pharmaceuticals (NASDAQ:ORMP)

Key Points

• Weiss Ratings reaffirmed a "Sell (D)" rating for Oramed Pharmaceuticals' stock (NASDAQ:ORMP) after its recently posted earnings.
• The company's stock opened at $2.39 and currently has a market capitalization of $97.99 million, reflecting a challenging financial position with a PE ratio of -6.83.
• Multiple institutional investors have increased their holdings in Oramed Pharmaceuticals, with BML Capital Management LLC raising its stake by 14.3% in the last quarter.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report)'s stock had its "sell (d)" rating reaffirmed by Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Oramed Pharmaceuticals Stock Up 0.8%

ORMP stock opened at $2.39 on Friday. The firm has a market capitalization of $97.99 million, a PE ratio of -6.83 and a beta of 1.62. Oramed Pharmaceuticals has a twelve month low of $1.82 and a twelve month high of $3.09. The stock has a 50-day simple moving average of $2.32 and a two-hundred day simple moving average of $2.23.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last posted its earnings results on Thursday, August 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.01). On average, equities research analysts anticipate that Oramed Pharmaceuticals will post -0.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ORMP. BML Capital Management LLC grew its holdings in shares of Oramed Pharmaceuticals by 14.3% during the first quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company's stock worth $6,464,000 after purchasing an additional 376,841 shares in the last quarter. Peapod Lane Capital LLC grew its holdings in shares of Oramed Pharmaceuticals by 11.0% during the first quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock worth $540,000 after purchasing an additional 24,985 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Oramed Pharmaceuticals by 35.3% during the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock worth $144,000 after purchasing an additional 17,510 shares in the last quarter. N.E.W. Advisory Services LLC grew its holdings in shares of Oramed Pharmaceuticals by 52.9% during the first quarter. N.E.W. Advisory Services LLC now owns 18,900 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 6,540 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in shares of Oramed Pharmaceuticals by 36.2% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 18,799 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 5,000 shares in the last quarter. Hedge funds and other institutional investors own 12.73% of the company's stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.